AIM — AIM ImmunoTech Income Statement
0.000.00%
Last trade - 00:00
- $23.20m
- $10.13m
- $0.20m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.14 | 0.163 | 0.135 | 0.141 | 0.202 |
Cost of Revenue | |||||
Gross Profit | -0.753 | -0.643 | -0.715 | 0.141 | 0.16 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 11.7 | 15.2 | 21.7 | 20.1 | 32.1 |
Operating Profit | -11.6 | -15 | -21.5 | -19.9 | -31.9 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.4 | -14.4 | -19.1 | -19.4 | -29 |
Net Income After Taxes | -9.4 | -14.4 | -19.1 | -19.4 | -29 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.4 | -14.4 | -19.1 | -19.4 | -29 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.4 | -14.4 | -19.1 | -19.4 | -29 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.07 | -0.485 | -0.363 | -0.436 | -0.63 |